Back to today’s briefing

Story perspectives

Merck Splits Division to Boost Cancer Care Leadership

2/23/2026

38 8 Full Breakdown

Summary

Story summary

Merck & Co. announced February 23, 2026 that it will split its Human Health division into Oncology and Specialty, Pharma & Infectious Diseases.
The move aims to strengthen Merck's leadership in cancer care as Keytruda's patent nears expiration.
Keytruda generated nearly 46% of Merck's revenue in 2024.
Jannie Oosthuizen has been appointed Oncology unit head at Merck & Co.
Chirfi Guindo will oversee strategic access and communications for Merck & Co.

1 of 1

Story summary

Merck & Co. announced February 23, 2026 that it will split its Human Health division into Oncology and Specialty, Pharma & Infectious Diseases.
The move aims to strengthen Merck's leadership in cancer care as Keytruda's patent nears expiration.
Keytruda generated nearly 46% of Merck's revenue in 2024.
Jannie Oosthuizen has been appointed Oncology unit head at Merck & Co.
Chirfi Guindo will oversee strategic access and communications for Merck & Co.